Business
IN8bio’s Announces Peer-Reviewed Publication of Preclinical Results Using Proprietary MGMT-modified Gamma-Delta T Cells (INB-200) with Temozolomide in Mouse Models of Glioblastoma Multiforme
Concurrent dosing of MGMT-modified gamma-delta T cells with Temozolomide (TMZ) demonstrated a significant survival benefit across multiple models of
About this update from In8bio, Inc.
[{"type":"text","content":"Concurrent dosing of MGMT-modified gamma-delta T cells with Temozolomide (TMZ) demonstrated a significant survival benefit across multiple models of high-grade glioma MGMT-modified gamma-delta T cells are engineered to survive chemotherapy and form the basis of IN8bio’s Drug Resistant Immunotherapy (DRI) technology These results, published online in the Nature portfolio journal Scientific Reports (DOI: https://doi.org/10.1038/s41598-021-00536-8), provide significant preclinical support for the clinical development of DRI DRI with a concurrent TMZ dosing regimen is currently being evaluated in a Phase 1 clinical trial in glioblastoma multiforme (GBM) at the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham (UAB) NEW YORK, Oct. 27, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced the peer-reviewed publication of preclinical results that provides foundational support for the use of DRI in newly diagnosed GBM. This work, published in the Nature portfolio journal Scientific Reports, focused on the use of gamma-delta T cells genetically engineered to be chemotherapy resistant through the addition of an O6-Methylguanine-DNA Methyltransferase (MGMT) transgene, a process termed Drug Resistant Immunotherapy (or DRI). Concurrent dosing of DRI cells with TMZ resulted in a significant improvement in survival outcomes in mice over either monotherapy alone in both classical and mesenchymal primary high-grade gliomas. These studies were performed by IN8bio’s scientific co-founder and Chief Scientific Officer, Dr. Lawrence Lamb while at UAB, in collaboration with researchers at Emory University, and the technology has been exclusively licensed world-wide by IN8bio. This unique technology forms the basis for the company’s DeltEx DRI platform, which utilizes ex-vivo expanded, activated gamma-delta T cells that can be engineered to be chemotherapy resistant for both solid and liquid tumors. This preclinical work provides support for the concurrent dosing of DRI cells with TMZ to debulk the tumor, reduce accumulation of immunosuppressive cells and upregulate innate effector cell activation through an increase in NKG2D-ligands. This approach is cu...